

Explore **affordable** and **accessible**  
cancer treatment for your practice



**TORIGEN<sup>®</sup>**

Over **4 million dogs** and **4 million cats** are diagnosed with cancer each year.


...yet only **1 in 10** owners see a veterinary oncologist.



Even though **50%** of dogs over the age of 10 will die from cancer, **90% of these dogs will never see a cancer specialist.**

# Why?

A lack of **accessible options** means most cancer patients remain with their primary care veterinarian.






**Torigen's autologous prescription product** is a personalized cancer vaccine made from the patient's own tumor cells.



We aim to **train the immune system** to fight cancer



- After a tumor is surgically excised, it is sent into our laboratory where we prepare a personalized treatment utilizing the patient's own tumor cells
- Our approach is called a Whole-Cell Autologous cancer vaccine that drives CD8+ immune recognition of tumor antigens
- We offer a simple and accessible treatment that can be completed with both oncologists and within general practice

#### Tumor types we treat

- Carcinomas (Adenocarcinoma)
- Sarcomas
- Mast cell tumors
- Melanoma
- Sarcoids

\* Regulated as an experimental product by USDA under 9 CFR 103.3.

Notice! For experimental use only. Autologous Prescription Product, Code 95A7.50 (unlicensed) is a service provided by Torigen Pharmaceuticals, Inc. and is regulated by the USDA Center for Veterinary Biologics. Treatment is administered only to the stated animal. Efficacy and safety have not been established by the USDA.

**Pet Parents**  
need alternative  
cancer treatment  
options that are more  
accessible than  
chemotherapy or  
radiation.




**TORIGEN<sup>®</sup>**  
has the solution.

**Veterinarians**  
need additional  
cancer treatment  
options in  
their practices.



Straightforward administration in **any clinical setting**.  
**No personal protective equipment required.**



We've treated over **2,500+** veterinary patients to date. Read our peer-reviewed publications below:





Our goal is to help pets with cancer while maintaining **quality of life.**

Safety Analysis	Canine <sup>1</sup>	Feline <sup>2</sup>
Population Size	93	117
Doses of Torigen Autologous Cancer Vaccine Administered	279	438
Doses Associated with an Adverse Event	12 (4.3%)	6 (1.4%)
Doses Associated with a Serious Adverse Event	1 (0.0%)	1 (0.2%)+


<sup>1</sup>Lucroy MD, Kugler AM, El-Tayyeb F, et al. Field safety experience with an autologous cancer vaccine in tumor-bearing cats: a retrospective study of 117 cases (2015 – 2020). J Fel Med Surg July 30, 2021

<sup>2</sup>Lucroy MD, Kugler AM, El-Tayyeb F, et al. Field safety experience with an autologous cancer vaccine in tumor-bearing cats: a retrospective study of 117 cases (2015 – 2020). J Fel Med Surg July 30, 2021

+ Suspect cancer-related death

Notice! For experimental use only. Autologous Prescription Product, Code 95A7.50 (unlicensed) is a service provided by Torigen Pharmaceuticals, Inc. and is regulated by the USDA Center for Veterinary Biologics. Treatment is administered only to the stated animal. Efficacy and safety have not been established by the USDA.

In a recent published study of canine metastatic hemangiosarcoma, Torigen Autologous Prescription product showed a similar survival to chemotherapy. In the chemotherapy group, **43% had an adverse event with 17% of dogs requiring hospitalization<sup>3</sup>** in comparison to 0 adverse events in the Torigen Autologous prescription product group.



<sup>3</sup>Lucroy MD, Clauson RM, Suckow MA, El-Tayyeb F, Kalinauskas A: **Evaluation of an autologous cancer vaccine for the treatment of metastatic canine hemangiosarcoma: a preliminary study.** BMC Vet Res – Submitted 2020



We work everyday to help pets with cancer. **This is all we do.**





Contact your **Torigen representative** to purchase a tumor collection kit.

FPO Business card

860.519.9956  
[www.torigen.com](http://www.torigen.com)